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Abstract
AIM: To determine renal dysfunction post liver trans-
plantation, its incidence and risk factors in patients 
from a Belgian University Hospital.
METHODS: Orthotopic liver transplantations per-
formed from January 2006 until September 2012 
were retrospectively reviewed (n  = 187). Patients 
with no renal replacement therapy (RRT) before 
transplantation were classified into four groups 
according to their highest creatinine plasma level 
during the first postoperative week. The first group 
had a peak creatinine level below 12 mg/L, the second 
group between 12 and 20 mg/L, the third group 
between 20 and 35 mg/L, and the fourth above 35mg/
L. In addition, patients who needed RRT during the 
first week after transplantation were also classified 
into the fourth group. Perioperative parameters 
were recorded as risk factors, namely age, sex, body 
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mass index (BMI), length of preoperative hospital 
stay, prior bacterial infection within one month, 
preoperative ascites, preoperative treatment with 
β-blocker, angiotensin-converting enzyme inhibitor or 
non steroidal anti-inflammatory drugs, preoperative 
creatinine and bilirubin levels, donor status (cardiac 
death or brain death), postoperative lactate level, 
need for intraoperative vasopressive drugs, surgical 
revision, mechanical ventilation for more than 24 h, 
postoperative bilirubin and transaminase peak levels, 
postoperative hemoglobin level, amount of perioperative 
blood transfusions and type of immunosuppression. 
Univariate and multivariate analysis were performed 
using logistic ordinal regression method. Post hoc 
analysis of the hemostatic agent used was also done.
RESULTS: There were 78 patients in group 1 (41.7%), 
46 in group 2 (24.6%), 38 in group 3 (20.3%) and 25 
in group 4 (13.4%). Twenty patients required RRT: 13 
(7%) during the first week after transplantation. Using 
univariate analysis, the severity of renal dysfunction was 
correlated with presence of ascites and prior bacterial 
infection, preoperative bilirubin, urea and creatinine 
level, need for surgical revision, use of vasopressor, 
postoperative mechanical ventilation, postoperative 
bilirubin and urea, aspartate aminotransferase (ASAT), 
and hemoglobin levels and the need for transfusion. 
The multivariate analysis showed that BMI (OR = 1.1, 
P  = 0.004), preoperative creatinine level (OR = 11.1, P  
< 0.0001), use of vasopressor (OR = 3.31, P  = 0.0002), 
maximal postoperative bilirubin level (OR = 1.44, P  = 
0.044) and minimal postoperative hemoglobin level 
(OR = 0.059, P  = 0.0005) were independent predictors 
of early post-liver transplantation renal dysfunction. 
Neither donor status nor ASAT levels had significant 
impact on early postoperative renal dysfunction in 
multivariate analysis. Absence of renal dysfunction 
(group 1) was also predicted by the intraoperative 
hemostatic agent used, independently of the extent of 
bleeding and of the preoperative creatinine level.
CONCLUSION: More than half of receivers experienced 
some degree of early renal dysfunction after liver 
transplantation. Main predictors were preoperative renal 
dysfunction, postoperative anemia and vasopressor 
requirement.
Key words: Liver transplantation; Acute kidney injury 
incidence; Perioperative complications; Acute kidney 
injury risk factors; Creatinine/blood; Severity renal 
failure
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: One hundred and eighty-seven liver trans-
plantations performed between 2006 and 2012 were 
retrospectively analyzed. Patients were classified into 
four groups according to their highest creatinine plasma 
level during the first postoperative week relying on 
sequential organ failure assessment renal classification. 
Perioperative parameters were recorded as risk factors. 
Univariate and multivariate analysis were performed. 
Fifty-eight percent of recipients experienced some 
degree of early postoperative renal dysfunction. The 
multivariate analysis showed that body mass index, 
preoperative creatinine level, use of vasopressor, 
hemostatic drug, postoperative bilirubin peak level and 
postoperative hemoglobin minimum level but not the 
donor status (cardiac dead or brain dead donor) were 
independent predictors of post-transplantation early 
renal dysfunction.
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INTRODUCTION 
Renal failure is one of the main complications after 
orthotopic liver transplantation (OLT), with severe 
impact on early and long-term outcomes[1]. Renal 
function could even predict patients’ survival before 
and after liver transplantation[2,3]. The prevalence 
of acute kidney injury (AKI) after OLT varies from 
12% to 70% according to AKI definition[4-7]. Its 
pathogenesis is multifactorial and includes functional 
pre-renal hyperazotemia and acute tubular necrosis or 
apoptosis[4,8]. Highlighting AKI risk factors associated 
with OLT may help to reduce the prevalence of early 
renal dysfunction (and improve global outcome) via 
the development of therapeutic strategies aiming at 
reducing these risks.
Extensive research has suggested that many 
preoperative factors may favour the occurrence of 
AKI after OLT such as preoperative kidney dysfunction 
and hepatorenal syndrome (HRS), pre-OLT low serum 
albumin level, hypovolemia, ascites, concomitant chronic 
diseases leading to kidney injury (diabetes mellitus, 
hypertension), hepatitis C (which is associated with 
multiple glomerular diseases including membranous 
glomerulonephritis, mixed essential cryoglobulinemia 
and membranoproliferative glomerulonephritis[9,10]), 
Child-Pugh score and Meld score[10-14], all with conflicting 
evidence. During surgery, kidneys have to deal with 
further insults such as hypovolemia, inferior vena cava 
clamping and its associated increased pressure at the 
kidney level, hemorrhage and anemia, hemodynamic 
instability, blood transfusion, extended surgical 
procedure and some particular surgical techniques[9,15,16].
Moreover, it is reported that renal function relies 
on the liver graft quality. Renal prognosis is deemed 
to be worse with organs issued from cardiac death 
donors[17].
Postoperative additional factors such as radiological 
contrast media, sepsis and immunosuppressive drugs 
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(calcineurin inhibitors) promote renal failure[9,18].
The primary goal of our single center retrospective 
study was to estimate the incidence and severity of 
early postoperative renal dysfunction in OLT recipients 
and to highlight the perioperative AKI risk factors and 
their significance. The role of donation after circulatory 
death (DCD) was particularly looked into.
MATERIALS AND METHODS
Data were collected from a consecutive series of 
patients who underwent OLT at the University Hospital 
of Liege (Belgium) from January 2006 until September 
2012. This analysis was limited to this time frame to 
avoid selection bias due to new recommendations in 
the handling of transplanted patients. We analyzed 
OLT patients developing acute renal failure (ARF) in 
the early postoperative course up to and including 
postoperative day 7 (primary outcome).
Data collection was based on a prospective clinical 
research database taking into account hospitalization 
data (preoperative hospital stay and infection 
occurrence), baseline demographic characteristics 
[age, gender, body mass index (BMI) and co-morbid 
conditions], preoperative clinical and biological data 
(urea, creatinine and bilirubin levels), periopera-
tive septic status, ascites, previous treatment with 
β-adrenoreceptor blockers, angiotensin-converting 
enzyme inhibitors (ACEI) and non-steroidal anti-
inflammatory drugs (NSAIDs). We did not exclude 
patients with HRS pre-OLT from the study but we 
excluded patients who required preoperative renal 
replacement therapy (RRT).
A single surgical team, all members of which were 
specifically trained in OLT, performed all procedures. 
Intraoperative collected variables included liver graft 
source (cardiac dead or brain dead donor), need for 
surgical revision, need for transfusion [type of blood 
product administered: red cells concentrate (RCC), 
fresh frozen plasma (FFP) or platelet] and need 
for vasoactive drugs. Furthermore, we secondarily 
analysed the impact of the hemostatic agent used 
(aprotinin until October 2007, tranexamic acid later on 
- the only significant modification to protocol during 
the study period).
Post operative data during the first week were 
collected: need for transfusion (amount and type 
of blood product on days 0, 1 and 7), postoperative 
day 1 lactate peak level, minimum hemoglobin level, 
need for vasopressors, time to extubation, bilirubin 
peak level, aminotransferases peak levels, urea 
and creatinine peak levels, need for postoperative 
RRT and immunosuppressive drugs (tacrolimus, 
cyclosporine A or other immunosuppressive drug). 
The local triple immunosuppressive regimen consisted 
of a calcineurin inhibitor (cyclosporine or tacrolimus), 
an antiproliferative drug and a corticosteroid. Whole 
blood levels of calcineurin inhibitor were measured 
by chemiluminescence microparticle immunoassay 
(Architect® from Abbott).
We separated patients into four groups according to 
their renal function (relying on sequential organ failure 
assessment score stratification), based on the highest 
creatinine plasma level during the first postoperative 
week. The first group had a creatinine level below 12 
mg/L, the second group between 12 and 20 mg/L, the 
third group between 20 and 35 mg/L, and the fourth 
above 35 mg/L. Patients who needed RRT during the 
first week after transplantation were also classified in 
the fourth group.
Statistical analysis
Statistical analysis was performed by the University’s 
biomedical statisticians.
Univariate analysis was performed to identify 
variables associated with primary outcome as potential 
confounders. The results are presented as mean and 
standard deviation for normally distributed variables or 
median (interquartile range) for non-normally distributed 
variables. Several variables underwent a logarithmic 
transformation in order to standardize their distributions. 
Normality was checked by Shapiro-Wilk’s test.
RRT: Comparisons between RRT and categorized 
variables were made by a χ 2 test whereas comparisons 
with continuous variables were made using logistic 
regression.
Comparisons between the 4 groups of renal dys-
function with categorized variables were made by a χ 2 
test whereas comparisons with continuous variables 
were made using ANOVA or the Kruskal-Wallis’ non-
parametric test according to normality of variables. 
Ordinal logistic regression was performed in order to 
take the groups’ order into account and hence renal 
dysfunction severity (group 4 “more severe” than 
group 3 “more severe” than group 2 “more severe” 
than group 1).
The results are considered as significant with an 
uncertainty level of 5% (P < 0.05). Statistical analyses 
were carried out using software SAS version 9.3.
Multivariate model 
Variables included in the model are variables with a 
P-value lower than 0.10 in univariate analysis. 
RESULTS
There were 78 patients in group 1 (41.7%), 46 in 
group 2 (24.6%), 38 in group 3 (20.3%) and 25 in 
group 4 (13.4%). Twenty patients required RRT: 13 
(7%) during the first week after transplantation (group 
4). There were 7 (3.7%) early deaths within 28 d after 
transplantation (Table 1).
Considering the 4 aforementioned groups, severity 
of renal dysfunction was correlated in univariate analysis 
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level among our whole OLT population, namely BMI, 
preoperative creatinine level, use of vasopressor, 
postoperative bilirubin peak level and minimum 
postoperative hemoglobin level. It is to be noted that 
neither the donor status (cardiac death or brain death) 
nor transaminase levels were independent risk factor 
for AKI (Table 2).
Post hoc analysis of renal data into two chrono-
logical groups according to the hemostatic agent used 
showed that the occurrence of AKI (group 2, 3 and 
4 together) was higher with tranexamic acid than 
with aprotinin, even when adjusting for preoperative 
creatinine (OR = 2.23, 95%CI = 1.13-4.41, P = 0.021) 
and regardless of the extent of bleeding (Table 3).
with patient BMI, ascites, prior bacterial infection, 
preoperative bilirubin, urea and creatinine levels, surgical 
revision, intraoperative vasopressor requirement, 
postoperative mechanical ventilation, postoperative 
urea, bilirubin, aspartate amino transferase (ASAT) peak 
levels and minimum hemoglobin levels, intensive care 
unit (ICU) length of stay and transfusion of each type of 
products (RCC, FFP and platelet cups).
Results are presented as mean ± SD if normal 
distribution, median (P25-P75) if non normal continuous 
variable, n (%) if categorical variable.
Using multivariate analysis, the ordinal multiple 
logistic regression analysis identified 5 independent 
predictors of increased postoperative creatinine peak 
Table 1  Univariate analysis for severity of post orthotopic liver transplantation acute kidney injury
Variable Whole group 
(n  = 187)
Group 1 
(n  = 78)
Group 2 
(n  = 76)
Group 3 
(n  = 38)
Group 4 
(n  = 25)
P  value between 
groups
Preoperative
Age (yr) 56 ± 10   54 ± 10   56 ± 10 58 ± 9 57 ± 12  0.055
Sex (male) 147 (79) 61 (78) 32 (70) 33 (87) 21 (84)  0.410
BMI(kg/m²)  26 ± 4.5 25 ± 4 26 ± 5 26 ± 5  26 ± 5.0  0.055
Hospital stay (d) 3 ± 8   2.2 ± 4.8     4.2 ± 12.9   2.7 ± 7.9 6.4 ± 9.6  0.150
Bilirubin (mg/L) 25 (12-66) 17.4 (8.7-44.8) 23.2 (13.1-60.6) 32.3 (15.8-64.9) 56.3 (23.1-115.0) < 0.0001
Creatinine (mg/L)    9.5 (7.4-12.3) 7 (6.6-9.3) 10.4 (8.0-12.7) 11.5 (9.3-14.5) 13.4 (6.6-16.0) < 0.0001
Urea (g/L) 0.47 ± 0.35 0.34 (0.20-0.42) 0.40 (0.30-0.59) 0.42 (0.33-0.68) 0.64 (0.38-0.92) < 0.0001
Ascites 138 (73) 50 (64) 37 (80) 30 (79) 21 (84)  0.015
β blockers   67 (37) 24 (31) 18 (39) 17 (46)   8 (33)  0.400
ACEI   18 (10)   8 (11) 4 (9)   4 (11) 2 (8)  0.770
NSAIDs   5 (3) 1 (1) 2 (4) 1 (3) 1 (4)  0.480
Prior bacterial infection   62 (33) 16 (20)    18 (39.1)    13 (34.2) 15 (60)  0.001
Intraoperative
DCD   63 (34) 25 (32) 17 (37) 12 (32)   9 (36)  0.790
Infection   50 (27) 17 (22) 12 (26) 13 (34)   8 (32)  0.140
Vasopressors   86 (46) 18 (23) 25 (54) 25 (66) 18 (72) < 0.0001
Surgical revision   45 (24) 12 (15) 12 (26) 11 (29) 10 (40)  0.009
Transfusion 169 (90) 66 (85) 44 (96) 37 (97) 22 (88)  0.060
Postoperative
Lactates D1(mg/L) 434 ± 230   394 (270-509)   375 (279-484)    428 (283-527)  435 (334-711)  0.200
Minimum hemoglobin (g/dL) 8.0 (7.0-9.2)    8.9 (7.8-10.3)  7.7 (6.7-8.5) 7.55 (6.8-8.5) 6.7 (6.5-8.0) < 0.0001
Bilirubin peak (mg/L)   40 (23-77.6) 37 (18-77) 32 (24-82)  51 (37-73)  60 (33-128)  0.006
ASAT (UI/L)    733 (372-1248)   554 (333-966)     804 (472-1988)  875 (399-1300)  822 (505-2458)  0.001
ALAT (UI/L)    617 (380-1068)   569 (332-941)     698 (399-1085)  546 (397-1113)  695 (407-1133)  0.260
Urea (g/L) 0.88 (0.6-1.3)    0.57 (0.46-0.69)    0.97 (0.80-1.14) 1.38 (1.21-1.64) 1.87 (1.52-2.18) < 0.0001
Mechanical ventilation > 24 h   56 (30) 18 (23)   9 (20) 16 (42) 13 (52)  0.003
Mechanical ventilation days      1 (1-2)    1 (1-1)    1 (1-1)    1 (1-2)    2 (1-2)  0.001
RRT   20 (11) 4 (5) 2 (4) 1 (3) 13 (52) < 0.0001
ICU stay (d)      3 (2-5)    2 (2-4)    3 (2-4)    5 (4-7)      6 (4-13)  0.005
Tacrolimus 177 (95) 77 (99) 43 (94) 35 (92) 22 (92)  0.089
Cyclosporin   21 (11) 5 (6)   7 (15)   6 (16)   3 (13)  0.170
Additional 
immunosuppressant
185 (98) 77 (99)   46 (100)   38 (100) 24 (96)  0.550
Transfusion RCC D0 (U) 1 (0-3) 0 (0-2) 2 (0-4) 2 (1-5) 2 (1-5)  0.001
Transfusion RCC D1 (U) 0 (0-1) 0 (0-0)    0 (0-1.5) 0 (0-2) 0 (0-4) < 0.0001
Transfusion RCC D7 (U) 2 (0-5) 0 (0-3) 3 (1-6) 4 (2-7)   4 (2-12) < 0.0001
Transfusion FFP D0 (U) 4 (2-6) 3 (0-6) 4 (2-7) 6 (3-9) 6 (3-8)  0.003
Transfusion FFP D1 (U) 0 (0-2) 0 (0-0) 0 (0-2) 2 (0-3) 2 (0-4) < 0.0001
Transfusion FFP D7 (U)   6 (2-10) 4 (1-6)      6 (2.5-10)   8 (4-11)   8 (6-15) < 0.0001
Transfusion platelets D0 
(CUP)
1 (0-1) 0 (0-1) 1 (0-1) 1 (0-1) 1 (1-2)   0.001
Transfusion platelets D1 
(CUP)
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-1)   0.002
Transfusion platelets D7 
(CUP)
1 (0-2) 0 (0-1)    1 (0-2.5) 1 (0-2) 2 (1-4) < 0.0001
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DISCUSSION
AKI remains a common disorder after OLT, despite 
advances in surgical technique, anesthesia, post-
operative care and immunosuppressive therapy. We 
found 58% of OLT recipients to have some degree of 
renal dysfunction highlighted by an increase in serum 
creatinine level during the first postoperative week. 
The rate of AKI varies among studies. Cabezuelo et 
al[4] and Rymarz et al[19] observed an AKI prevalence 
of around 30% over the first week after surgery, while 
Junge et al[10] found only 12% patients developing AKI 
during the first week after OLT. The incidence of post-
transplantation acute renal dysfunction is related to an 
increased mortality rate[20,21].
RRT requirement
When focusing on AKI severity, RRT requirement 
concerned 20 on 187 of our patients (11%), 13 (7%) 
of them within the first postoperative week. Likewise, 
in Faenza’s study[22], 8% of OLT patients experienced 
ARF requiring RRT during the postoperative period. 
They found that ARF requiring RRT conferred an 
excessive risk of in-hospital mortality (n = 8, 40%). 
This increased risk cannot be explained solely by a 
more pronounced severity of illness and provides 
evidence that ARF is a specific, independent risk factor 
for a poor prognosis[22]. According to the literature, 
3 to 20% of RRT-naïve patients who undergo OLT 
ultimately require postoperative RRT[23] with an 
associate increase in mortality rate[13,24].
Our results identified five parameters indepen-
dently associated with a postoperative increased 
serum creatinine level.
Preoperative renal impairment
Some degree of preoperative renal impairment was 
a main factor highlighted by our study, as shown by 
others[4,10,12,19], especially since biological markers 
are delayed and reflect advanced renal damages[25]. 
Intrinsic chronic kidney disease predisposes patients 
with end-stage liver failure to acute renal dysfunction[26]. 
Furthermore, hemodynamic preoperative factors 
promote the risk of ARF in cirrhotic patients: kidney 
hypoperfusion is due to intravascular hypovolemia 
associated with parietal edema, hypoalbuminemia 
and hormone-induced vasodilatation of splanchnic 
circulation[26,27]. Renin angiotensin aldosterone axis is 
also disturbed. Edema of renal parenchyma itself can 
also play a role in this phenomenon[28].
A link between acute liver failure (ALF) and ARF 
is described in the literature. Seventy percent of 
patients with ALF developed AKI, and 30% received 
RRT. Patients with severe ARF had higher international 
normalized ratio values, more severe encephalopathy 
and shock than patients without renal dysfunction[29]. 
Vasopressor requirements
Like other authors, we observed an adverse role of 
vasoconstrictor therapy during surgery[13]. Nevertheless, 
maybe vasopressor requirement rather than vaso-
pressor use is responsible for renal impairment. With 
cirrhosis, systemic arterial vasodilation is observed. 
Indeed, portal hypertension is associated with a 
release of vasodilatory substances (NO, prostacyclins). 
Moreover, vasodilation opens arteriovenous shunts. As a 
result, a hyperkinetic syndrome with an increase in the 
cardiac flow and a fall of the systemic blood pressure is 
observed in cirrhotic patients. During surgery, significant 
hemodynamic disturbances occur following liver 
mobilizations (dislocation), in addition to hepatomegaly 
in some cases, inducing a venous return decrease. 
Massive blood losses can occur especially in presence of 
adherences. Inferior cava vein clamping reduces once 
more venous return (up to 60%) and decreases cardiac 
flow (about 40% to 60%). Clamp withdrawal increases 
transient severe hypotension. 
A surgical revision is needed when significant 
bleeding persists after correction of biological coa-
gulation parameters, leading to anemia, hypotension, 
tissue hypoperfusion and cellular oxygen deprivation. 
These situations are associated with greater hemo-
dynamic instability leading to renal hypoperfusion.
Sepsis-associated vasodilation further increases 
these circulatory derangements. Sepsis-related AKI 
doesn’t seem to be related to renal global hypoperfusion 
but rather to renal hyperhemia with an intra-renal 
blood flow redistribution. The exact pathophysiology 
of sepsis-induced AKI is still not clear and seems 
multifaceted, with components of inflammatory 
Table 2  Multivariate analysis for increased post orthotopic 
liver transplantation serum creatinine level
OR 95%CI P  value
BMI (kg/m²)   1.10 1.03-1.18    0.0044
Preoperative increased 
creatinine (ln - mg/L)
11.07   5.28-23.23 < 0.0001
Vasopressors use   3.31 1.75-6.29    0.0002
Postoperative minimum 
Hemoglobin (ln - g/dL)
  0.06 0.01-0.29    0.0005
Postoperative bilirubin peak 
(ln - mg/L)
  1.44 1.01-2.05  0.044
BMI: Body mass index; ln: Natural logarithm.
Table 3  Post hoc multivariate analysis highlighting the effect 
of anti-hemorragic treatment strategy on acute kidney injury 
occurrence
Risk not being into the 1th group in 
multivariate analysis
OR 95%CI P  value
Antihemorragic treatment period 3.36 1.44-7.85  0.005
Preoperative increased creatinine 
(ln - mg/L)
1.36 1.20-1.54 < 0.0001
Bleeding (100 mL) 1.03 1.01-1.06  0.011
ln: Natural logarithm.
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injury, ischemia-reperfusion injury, endothelial cell 
dysfunction, coagulation disturbance and apoptosis[30]. 
Moreover, recent findings suggest that pathophysiologic 
mechanisms of sepsis-induced AKI are different from 
non-septic AKI[31].
It is reported that vasoplegia-induced hypotension 
is correlated with progressive AKI during severe 
sepsis, relying on the Finnaki study’s results[32]. On the 
other hand, generous fluid infusion and fluid overload 
in septic patients are also associated with progressive 
AKI[33,34]. 
Anemia and transfusion requirements
We found a significant impact of both postoperative 
anemia and transfusions on the incidence of early AKI. 
ARF severity was correlated to all transfused blood 
products in univariate analysis.
Data issued from literature are somewhat incon-
sistent regarding the effect of anemia and transfusion 
on renal function.
Villanueva et al[35] did not found any significant 
repercussion on the occurrence of acute kidney injury 
of different transfusion strategies with hemoglobin 
thresholds of 7 g/dL and 9 g/dL in 921 patients with 
upper gastro intestinal bleeding.
On the other hand, AKI is thought to happen 
when a combination of insults inducing renal hypoxia, 
inflammation and oxidative stress occurs in vulnerable 
patients[36,37]. Kidneys are known to be highly vulnerable 
to hypoxic injury in the setting of reduced oxygen 
delivery because of anemia[38,39]. Decreased renal 
oxygen delivery is due to hypotension, hemodilution 
and impaired renal blood flow.
On one hand, several studies have highlighted 
the harmful effect of the need for transfusion on 
renal function of liver recipient patients[11]. As a 
matter of fact, transfused erythrocytes may favour 
kidney injury because of the functional and structural 
alterations that they undergo during storage[40]. These 
include depletion of adenosine triphosphate and 
2,3-diphosphoglycerate, loss of ability to generate 
nitric oxide, increased adhesiveness to vascular 
endothelium, release of pro-coagulant phospholipids, 
accumulation of pro-inflammatory molecules as 
well as free hemoglobin and iron[40,41]. Furthermore, 
erythrocytes undergo progressive structural changes 
during storage that lead a considerable proportion 
(up to 30%) of them to be rapidly removed from the 
circulation by macrophages[42], which may then release 
some of scavenged hemoglobin-iron complexes into 
circulation[43,44]. As a result, stored erythrocytes may, 
at least for a few hours after they are transfused, 
paradoxically weaken tissue oxygen delivery, enhance 
the inflammatory cascade, and worsen tissue oxidative 
stress[39,40,45,46]. Furthermore, a significant need for 
intraoperative transfusion of all type of blood products 
in previously non anaemic patient can be a reflection 
of either a more severe preoperative liver dysfunction 
with severe coagulation impairment, or a prolonged 
intervention with surgical difficulties and hemodynamic 
alterations. In contrast with what precedes, some 
authors even recommend an increased intraoperative 
vasopressor use aiming at reducing transfusion 
requirement. It is reported that norepinephrine can 
improve outcome and reduce mechanical ventilation 
duration without effect on renal function when 
comparing a restrictive fluid strategy and a liberal fluid 
strategy called placebo during OLT surgery[47].
Obviously, a particular attention must be paid for 
hemostasis and coagulation optimization.
Finally, there is a theoretical anti ischemic precon-
ditioning effect of aprotinin, selective cyclooxygenase-2 
inhibitors and oral anti-diabetics (sulfonylurea, glita-
zones) which inhibit potassium channels[48]. Aprotinin 
is not used anymore and has been replaced by 
tranexamic acid to limit blood losses. The unique major 
modification in intraoperative management of liver 
transplant recipients in our center is the discontinued 
use of aprotinin in October 2007 (it was pulled out 
from international market given the concern that 
aprotinin increased risk of complication and death 
in the intraoperative period). Paradoxically, when 
stratifying renal data in two groups according to the 
antihemorrhagic agent used, we observed that the 
occurrence of renal failure was higher with tranexamic 
acid than with aprotinin, even when adjusted for 
preoperative creatinine level. This effect was not in 
relation with an increased intraoperative bleeding.
Hyperbilirubinemia
Because of donors’ paucity, sub optimal transplants 
coming from living donors, split or domino pro-
cedures and cardiac death donors often result in 
early hyperbilirubinemia, which is deemed to be 
due to suboptimal graft[49]. Hyperbilirubinemia 
is due to miscellaneous etiologies such as small 
for size syndrome and aged living donor, acute 
cellular rejection, graft preservation injury, surgical 
complications, sepsis or drug toxicity[50] with a higher 
prevalence in the context of living donors in the 
literature. Serum bilirubin level is a useful predictor of 
short-term (< 1 year) graft poor outcome[51].
Early postoperative hyperbilirubinemia can 
be considered as a sign of liver impairment from 
different causes (i.e., surgical complications, infection 
or acute graft rejection) but it may in itself also 
potentiate other insults such as kidney failure[52]. 
When early hyperbilirubinemia is not an isolated 
phenomenon but presents with hepatocellular failure, 
i.e., persistent coma, coagulopathy and elevated 
serum transaminase level, it is encompassed in the 
diagnosis of “primary non function” (or less severe 
early allograft dysfunction). In this particular situation, 
the patient also needs to be on prolonged mechanical 
ventilation and requires iterative transfusions. A rapid 
new liver transplantation is mandatory under these 
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circumstances. Primary non function is described as 
more frequent after “uncontrolled DCD donors” (i.e., 
with a prolonged warm ischemia) and believed to be 
the consequence of severe I-R injury in relation with 
warm injury[53]. Delayed bilirubin increasing is often 
due to biliary complications (bile leakage and bile duct 
stricture).
Ischemia-reperfusion
Besides aforementioned hemodynamic phenomena, 
liver ischemia-reperfusion (I-R) injury occurs after 
liver transplantation and circulatory shock, leading 
to significant morbidity and mortality. There is 
substantial evidence towards hepatic I-R injury 
resulting in an intense inflammatory response initiated 
by oxidative stress in the liver parenchyma during 
reperfusion. Hepatic I-R injury is associated with a 
systemic inflammatory response syndrome through a 
combination of immunologic, toxic and inflammatory 
factors (cytokines release), which can cause AKI 
through hemodynamic mechanisms and direct tubular 
cell death[30,54-57]. 
Nevertheless, unlike previous studies[17,58,59], we did 
not find any significant relationship between DCD and 
renal dysfunction. In 2012, Leithead et al[58] published 
the results of a single-center study conducted on 88 
consecutive DCD liver transplant recipients. During 
the immediate postoperative period, DCD liver trans-
plantation was associated with an increased incidence 
of AKI compared with donation after brain death (DBD). 
Interestingly, increased perioperative peak ASAT, a 
surrogate marker of hepatic ischemia reperfusion 
injury, was the only significant predictor of renal 
dysfunction after DCD transplantation. Organs recovered 
from a DCD have some degree of oxygen deprivation 
during the time after the heart stops beating, which is 
called warm ischemia. One of the explanations of the 
lower impact of DCD on renal function in our data, in 
comparison with Leithead’s studies, may be related 
to the differences in the legislation between the two 
countries. In the United Kingdom, discontinuation 
of therapy for DCD is carried out in the ICU, in the 
same condition than withdrawal of active treatment 
for a patient who is not a potential donor, e.g., in the 
presence of the family. Organ donation may not be 
possible if the dying process is prolonged and may 
result in an unacceptable warm ischemic time[60]. 
Moreover, warm ischemia increases graft susceptibility 
to damages induced by cold injury.
The Belgian legislation authorizes treatment 
withdrawal (in the context of the DCD) within the 
operating theatre, which reduces considerably warm 
ischemia duration. Two minutes are awaited after 
circulatory arrest before establishing death followed 
by a 5-min “no touch” phase before skin incision[61]. 
This enables the warm ischemia time to be as short as 
possible. 
Another sensitive ethical issue in DCD concerns 
organ preservation measures to protect organ viability 
until transplantation[62]. A tool to reduce I-R impact lies 
in preconditioning operations. Preconditioning consists 
of an improvement of the tolerance to ischemia 
(for 1 to 2 h) by brief episodes of flow occlusion or 
pharmacological means[63-65].
Preconditioning by halogenated anesthetics is related 
to several cellular mechanisms partially elucidated, 
such as the ATP dependant potassium channel opening 
(preserving mitochondrial function) and mitochondrial 
permeability transition pore closure [reducing the 
amount of radical oxygen species (ROS)][66-69]. These 
phenomena correspond to the early phase of the 
cellular protection; its duration is limited to 1-2 h. 
Preconditioning technique is possible only for a surgery 
where ischemia is programmed. Sevoflurane has also 
a protective effect on renal function (cystatine C) after 
coronary bypass surgery according to a double blinded 
multicenter study[67]. Pharmacological preconditioning 
by volatile anesthetics may protect non-cardiac organs 
against I-R[68,69].
Leithead et al[17] also showed an association be-
tween cold ischemic time (CIT) and perioperative AKI. 
These findings strongly suggest that a sustained 
CIT is a causative factor for poor outcome (of the 
transplanted organ but also global) after DCD liver 
transplantation[70]. Cold ischemia duration corresponds 
to the time elapsed between infusion of preservation 
fluid and the moment when the graft is perfused in 
the receiver. Shorter the time, better the results of 
transplantation. Beyond 13 h of cold ischemia on a 
whole liver, the risk of primary non-function becomes 
important. In addition to its non-specific effects, cold 
ischemia enhances graft immunogenicity and host 
allo-responsiveness. The ischemic injury, a localized 
process of cellular metabolic disturbances, results from 
glycogen consumption, lack of oxygen supply and 
adenosine triphosphate (ATP) depletion[71]. Reperfusion 
abruptly reintroduces large amount of oxygen in the 
previously deprived cells. The mitochondrial respiratory 
chain, functionally damaged by ischemia, cannot 
accurately use this excess of oxygen. The reactivation 
of the ionic pumps rapidly corrects the acidosis, but at 
the cost of a sodium and calcium overload, potentially 
very harmful for the cell. Instead of synthesizing 
ATP, mitochondrion produces free ROS. It leads, by 
lipidic peroxidation, to cellular membranes damages 
(including mitochondrial membrane), but also to 
an indirect inflammation activation by leucocytes 
recruitment and by stimulating cytokines production, 
especially tumor necrosis factor-alpha (TNF-α) and 
interleukin-1 beta[72-74]. Cytokines are mainly produced 
in the liver by the Kuppfer cells[75] but also by the 
extra-hepatic macrophages[76]. TNF-α propagates the 
inflammatory response[77]. Cytokines induce a local 
and general inflammatory syndrome followed by tissue 
edema. At reperfusion, body is flooded by degradation 
substances, such as lytic enzymes (ASAT, lactate 
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dehydrogenase), lactates, potassium, H+ ions… which 
can induce severe metabolic acidosis, renal failure, 
ARDS, heart failure or even multiple organ failure[78]. A 
similar situation is observed with the harmful remote 
effects of mesenteric I-R, where released mediators 
are involved in multi organ failure occurrence[79]. I-R 
phenomenon may clarify the stronger association we 
found between ASAT and AKI than between alanine 
amino transferase (ALAT) and AKI, even if ALAT is 
more liver specific than ASAT. 
Eurotransplant is responsible for allocation of donor 
organs in Belgium. A match list is generated by a 
computer algorithm that takes into account all medical 
and ethical criteria. Another potential explanation of 
the difference between Leithead’s report and our data 
perhaps relies on the policy of preferential allocation 
by Eurotransplant of an organ coming from a DCD 
to the donor’s transplantation center (to reduce cold 
ischemic duration in those organs which have already 
experienced warm ischemia).
The recipient selection is also important since 
organs coming from a DCD are selectively reserved 
to uncomplicated cases to ensure short cold ischemic 
time (by avoiding cases with extensive history of 
abdominal surgery or portal-vein thrombosis)[53].
Likewise in our study, a recent meta-analysis 
focusing on post OLT complications also failed to detect 
a significant difference in complication rates (inclu-
ding renal failure) in the subgroup of cardiac death 
donors[80].
Immunosuppressive drugs
Unexpectedly, we did not found any significant impact 
of immunosuppressive drugs on early AKI. Never-
theless, nephrotoxicity associated with calcineurin 
inhibitors (CNI), e.g., cyclosporine and tacrolimus, is 
common and occurs either acutely or after chronic use. 
Acute injury is believed to be dose and concentration-
dependent. However, it may be observed in patients 
with therapeutic blood concentrations. CNI-induced AKI 
is believed mainly to come from afferent glomerular 
arteriolar vasoconstriction, reduced renal blood flow 
and ultrafiltration coefficient and, as a result, decreased 
glomerular filtration rate. This may be attributable to 
an increased production of vasoconstrictive factors 
(such as thromboxane A2 and endothelin) together 
with a decrease in renal vasodilatory prostaglandins 
and inhibition of nitric oxide[9,18,81-84]. CNI-associated 
AKI may develop early in therapy. It can occur within 
a few days after the initiation of either cyclosporine or 
tacrolimus. Early CNI-induced AKI generally improves 
once the cyclosporine or tacrolimus dose is reduced 
or discontinued. In contrast, late CNI-induced chronic 
renal failure is associated with interstitial nephritis and is 
usually irreversible[18-82].
In our institution, usual immunosuppressive the-
rapy is based on low dose tacrolimus (serum target 
of 5-8 ng/mL), mycophenolic acid and steroids. It 
corresponds to the renal sparing immunosuppression 
regime in other studies[17,58,59,85], where renal sparing 
immunosuppression could significantly reduce early 
kidney dysfunction in comparison with their standard 
immunosuppressant treatment with CNI (serum 
tacrolimus target of 8-10 ng/mL), azathioprine and 
decreasing dose of steroids.
Limitations
Serum creatinine is the most established, simple, 
and inexpensive estimation of renal function. It is 
the primary method of detection of all forms of renal 
failure. Usually, monitoring renal function mostly relies 
on the results of the serum creatinine level and the 
estimated glomerular filtration rate calculated with the 
use of Levey’s modification of diet in renal disease and 
Cockcroft-Gault formulas with an additional monitor-
ing of diuresis. Relying on the Risk Injury Failure Loss 
and End-stage renal disease (RIFLE) classification 
introduced in 2002, modified as AKI network (AKIN) 
classification since 2005, the AKI term currently 
integrates a wide range of renal dysfunctions, starting 
with a very early and slight renal dysfunction with 
minimal changes in the serum creatinine level (stage 1, 
risk), through moderate changes (stage 2, injury), to 
an advanced renal failure (stage 3, failure).
One limitation of the study is the lack of use of the 
RIFLE, AKIN or more recent Kidney Disease Improving 
Global Outcomes criteria to define the degree of acute 
kidney injury. Moreover, as well in our study than in all 
the AKI definitions mentioned above, the use of serum 
creatinine (sCr) as renal dysfunction marker is also 
questionable in the context of liver failure. 
Even if sCr remains the most practical biomarker 
and the most commonly used for renal function 
evaluation, it presents many weaknesses in clinical 
practice since it is influenced by body weight, muscle 
mass, race, age, gender, protein intake and muscle 
metabolism. Body weight and muscle mass probably 
explain why BMI is an independent significant factor 
of postoperative increased creatinine level. In the 
particular case of a cirrhotic patient, it is also affected 
by a decreased formation of creatinine from muscles 
(due to muscle waste)[86], a decreased hepatic 
capacity to produce creatinine, an increased renal 
tubular secretion of creatinine[87], a low dietary protein 
intake to avoid hyperammonemia[7], an impairment 
of creatinine dosage with bilirubin high level[88] and 
an increased volume of distribution responsible for 
dilution of sCr. As a consequence, measurements of 
sCr in patients with cirrhosis overestimate glomerular 
filtration rate (GFR) or kidney function. Even more, 
creatinine is not an early reflection of GFR variations 
(substantial rises in serum creatinine are often 
not witnessed until 48-72 h after the initial kidney 
insult[89,90]) and rapid deterioration of renal function 
can be underestimated in the first days. In addition, 
significant renal disease can exist with minimal or 
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no change in creatinine because of renal reserve or 
enhanced tubular secretion of creatinine[91,92]. On the 
other hand, slight modifications of serum creatinine 
level can be due to variation of body water content, 
corresponding to a false positive elevation. Although 
a decreased urinary output is the second criteria 
used in all those scores, it is admitted that use of 
urinary output in patients with cirrhosis and ascites is 
inadequate since these patients suffer from sodium 
retention and often present oliguria, even if they have 
a relatively preserved GFR[93]. Moreover urinary output 
is frequently artificially enhanced by use of diuretics.
A “troponin-like” biomarker of AKI that is easily 
measured, unchanged by other biological variables, 
and capable of both early detection and risk stra-
tification would considerably help for the diagnosis 
of AKI. It has been proposed that new biomarkers 
of renal function may be added to the diagnosis of 
AKI[94]. Nevertheless, recent studies focusing on 
critical patients have shown disappointing conclusions 
regarding the impact of routine use of neutrophil 
gelatinase-associated lipocalin (NGAL) analysis[95-97]. 
Anyway, by using serum creatinine evolution for 7 d 
after transplantation, we estimated that a perioperative 
event would be emphasized by an increase in creatinine 
level, even with a 48 h delay in comparison with other 
biomarkers such as NGAL[98]. The aim of this study was 
not here to detect a renal damage as quickly as possible 
but to highlight all the perioperative factors which may 
affect kidney function. 
On the other hand, we only excluded from our 
analyses patients with previous renal failure requiring 
RRT (but not patients with moderate renal dysfunction). 
Even if it is easily conceivable that a kidney with less 
reserve will be more prone to functional deterioration 
compared to a healthy kidney, our study design reflects 
more real life situation in ICU management of AKI post 
OLT, taking into account that patients without previous 
oliguria or elevated serum creatinine could indeed have 
lost a substantial number of nephrons.
In conclusion, our study demonstrated that AKI 
after liver transplantation is a common complication 
since more than half of liver transplanted patients 
experienced some degree of early renal dysfunction after 
transplantation. BMI, hyperbilirubinemia, preoperative 
renal dysfunction, peroperative circulatory instability 
requiring the use of vasopressor and postoperative 
anemia are independent predictors of AKI occurrence.
Despite the reputable poor quality of the graft in 
DCD, neither comparison between DCD and DBD, 
nor ASAT level were associated with post-OLT AKI by 
multivariate analysis.
Besides targeting improvement of graft quality, a 
particular attention must be paid to avoid preoperative 
additive kidney damages, to optimize intraoperative 
hemodynamics and to consider treatment in order to 
reduce transfusion requirements.
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COMMENTS
Background
Acute renal dysfunction is a frequent complication in the perioperative period of 
liver transplantation, with an impact on renal and vital outcomes in some cases. 
Moreover, acute renal failure has multifactorial etiologies with possible complex 
interactions.
Research frontiers
Since acute renal failure is frequent and may result from multiple etiologies 
with additional extra renal confounding factors and, moreover, is delayed from 
its cause, there is no unique treatment to prevent or resolve renal dysfunction. 
Highlighting significant risk factors of renal dysfunction should allow focusing on 
these parameters and reducing their impact in the future.
Innovations and breakthroughs
The authors found a high prevalence of perioperative renal dysfunction after 
liver transplantation. Previous studies evaluated the late renal impact after liver 
transplantation and prolonged immunosuppressive treatment, but few of them 
focused on the perioperative period to highlight renal repercussions at that 
time-limited but crucial period. Among studies focusing on renal function during 
early postoperative period, organs from donation after cardiac death (DCD) 
seemed to be associated with more renal dysfunction than with liver from 
brain dead donors. The authors did not find the same association. It seems 
extremely important since donor shortage will lead to an increasing proportion 
of transplantations from DCD rather than from donation after brain death.
Applications 
The authors observed that preoperative renal dysfunction, body mass index 
(BMI), vasopressor, postoperative low hemoglobin and high bilirubin levels 
were independent risk factors for developing renal dysfunction. While it seems 
difficult to act on BMI or on previous renal function, optimizing hemodynamics 
and coagulopathy management appears useful. 
Terminology
Acute renal dysfunction is defined as a sudden reduction in renal filtration 
ability, induced by one or more harmful phenomena. It leads to serum ions 
imbalance, blood accumulation of waste substances, fluid retention and 
metabolic acidosis. Acute renal failure can be fatal and requires intensive 
treatment. Nevertheless, it may be a reversible condition. Early postoperative 
period is defined in this study as the first week following liver transplantation. 
When focusing on renal function, since usual (bio)markers of renal failure are 
delayed, this period reflects hemodynamic and metabolic changes encountered 
just before, during and immediately after surgical intervention (early surgical 
complications). Donation after cardiac/circulatory death and donation after brain 
death: Donation after circulatory death is a donor in refractory cardiac arrest 
or suffering from devastating and irreversible organ injury (usually brain injury) 
and awaiting cardiac arrest, but who does not meet formal brain death criteria. 
In these later cases, it is decided to withdraw care. When the patient’s heart 
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stops beating, the organs are harvested in the operating room. Organs from 
a cardiac dead donor have some degree of oxygen deprivation during warm 
ischemia, i.e., the time after the heart stops beating. Donation after brain death 
occurs when a person has a disastrous and irreversible brain injury, which 
causes total cessation of all brain function (including upper brain structure and 
brain stem). Brain death is not a coma nor a vegetative state but a real dead 
condition where cardio respiratory function is sustained by artificial devices (e.g., 
mechanical ventilation). 
Peer-review
The manuscript is a single center retrospective study that aims at estimating 
the incidence and severity of early postoperative renal dysfunction in orthotopic 
liver transplantation recipients and at highlighting the perioperative acute kidney 
injury risk factors and their significance, with particular attention to the role of 
DCD. The manuscript is well-written and deserves publication, as it carries a 
useful message to the clinicians involved in transplantation.
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